Anup Mishra, Chairman, Fortis, CDOC Hospital for Diabetes, and Allied Sciences, Chandrakanth Lahariya, Health and Social Sector Policy Advisor, Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals, Ramya Kannan, Chief Of Bureau, Tamil Nadu, The Hindu during the The Hindu Huddle.
| Photo Credit:
K. Bhagya Prakash
The explosive popularity of GLP-1 (Glucagon-Like Peptide-1) drugs for addressing weight loss, diabetes and obesity, such as Ozempic and Munjaro are useful for a limited number of people and will not solve the obesity or diabetes crisis that India is battling, said Dr Anoop Misra, Chairman, Fortis Centre of Diabetes, at The Huddle by The Hindu on Saturday.
Published – May 11, 2025 10:36 am IST
